Back

Illumina Inc

Ticker: ILMN ISIN: US4523271090
Add to portfolio Portfolio analysis in 2min
Stock Large-cap High beta Trading above 200-day average Near 52-week high
Market cap
$20.99B
P/E
25.22
Forward P/E
27.47
Profit margin
19.42%
Revenue growth QoQ
4.80%
Beta
1.42
$265.72 -2.91%
Price as of 2026-10-01 · NASDAQ

Performance by timeframe

Rolling returns
1 Month +24.60%
6 Months +108.02%
1 Year +167.59%
5 Years -6.39% p.a.-28.09%
10 Years +4.19% p.a.+50.73%
Since inception +19.79% p.a.+8,990.04%
Calendar year returns
YTD +102.59%
2025 -1.85%
2024 -1.34%
2023 -31.14%
2022 -46.85%
2021 +2.82%

Key stats

Market cap
20.99B
P/E
25.22
Beta
1.42
52-week range
77.50 - 155.53
50-day MA
127.38
200-day MA
118.89
Section 1

Business overview

Company profile data from fundamentals.

Illumina, Inc. provides sequencing- and array-based solutions for genetic and genomic analysis in the Americas, Europe, Greater China, the Asia Pacific, the Middle East, and Africa. The company offers sequencing- and array-based instruments and consumables, which include reagents, flow cells, and library preparation; whole-genome sequencing kits, which sequence entire genomes of various size and complexity; and targeted resequencing kits, which sequence exomes, specific genes, and RNA or other genomic regions of interest. It also provides whole-genome sequencing, genotyping, noninvasive prenatal testing, and product support services. The company serves genomic research centers, academic institutions, government laboratories, and hospitals, as well as pharmaceutical, biotechnology, commercial molecular diagnostic laboratories, and consumer genomics companies. The company markets and distributes its products directly to customers, as well as through life-science distributors. The company has a collaboration with Labcorp Holdings Inc. for the development of oncology treatments through applications of sequencing solutions across the healthcare ecosystem. It also has a data partnership with Center for Data-Driven Discovery in Biomedicine to advance research in pediatric cancer and rare disease. Illumina, Inc. was incorporated in 1998 and is headquartered in San Diego, California.

Sector Healthcare
Industry Diagnostics & Research
Country United States
Exchange NASDAQ
Section 2

Financial quality

Above-average volatility

Profitability and balance-sheet quality indicators from reported fundamentals.

Profitability

ROE 33.82%
ROA 8.68%
Profit margin 19.42%
Operating margin 18.33%
PEG ratio 2.52
Revenue/share TTM 28.62
Revenue TTM 4.39B
EBITDA 1.16B
Gross profit TTM 3.00B
Beta 1.42

Valuation

Trailing P/E 25.22
Forward P/E 27.47
P/B 8.06
P/S 4.78
EV/EBITDA 16.05
EV/Revenue 5.23
Section 3

Earnings

Earnings metrics from company highlights and earnings datasets.

EPS estimate (current year) 5.22
Quarterly earnings growth 6.10%
Revenue TTM 4.39B
Section 4

Ownership / analyst view

Institutional ownership and analyst estimate fields when available.

Ownership & short interest

Short ratio 5.05
Short % of float 7.70%

Details

Instrument metadata and source update timestamps.

Symbol ILMN
Name Illumina Inc
Asset type STOCK
Exchange NASDAQ
Currency USD
ISIN US4523271090
Country USA
Code + exchange ILMN.NASDAQ
Fundamentals updated 2026-05-08

The information provided on this platform is for informational purposes only and should not be considered as financial or investment advice. Insightfolio does not provide investment advice, personalized recommendations, or guidance regarding the purchase, holding, or sale of financial assets. The tools and content are intended for educational purposes only and are not tailored to individual circumstances, financial needs, or objectives.

Insightfolio assumes no liability for the accuracy, completeness, or reliability of the information presented. Users are solely responsible for verifying the information and making independent decisions based on their own research and careful consideration. Use of the platform should not replace consultation with qualified financial professionals.

Investments involve risks. Users should be aware that the value of investments may fluctuate and that past performance is not an indicator of future results. Investment decisions should be based on personal financial goals, risk tolerance, and independent evaluation of relevant information.

Insightfolio does not endorse or guarantee the suitability of any particular financial product, security, or strategy. Any projections, forecasts, or hypothetical scenarios presented on the platform are for illustrative purposes only and are not guarantees of future outcomes.

By accessing the services, information, or content offered by Insightfolio, users acknowledge and agree to these terms of the disclaimer. If you do not agree to these terms, please do not use our platform.

Instrument logos provided by Elbstream.